Antibodies targeting M-CSF

Patent metadata

Field	Value
Publication number	US-9856316-B2
Application number	US-201414781601-A
Country	US
Kind code	B2
Filing date	Apr 11, 2014
Priority date	Apr 12, 2013
Publication date	Jan 2, 2018
Grant date	Jan 2, 2018

Abstract

This disclosure generally relates to antibodies or antibody fragments which specifically bind to M-CSF. In particular antibodies and antibody fragments are disclosed which bind to M-CSF and which inhibit binding of M-CSF to the M-CSF receptor with an IC50 of 10 pM or less. The invention also relates to nucleic acids, vectors and host cells capable of expressing the antibodies or fragments thereof of the invention, pharmaceutical compositions comprising the antibodies or fragments thereof and uses of said antibodies or fragments thereof and compositions for treatment of specific diseases.

First claim

The invention claimed is:

1. An isolated antibody or antibody fragment which specifically binds to M-CSF wherein said isolated antibody or antibody fragment is able to inhibit the binding of M-CSF to the M-CSF receptor with an IC50 of 10 pM or less in a receptor binding inhibition assay comprising M-CSF at a final concentration of 12.5 pM and wherein said antibody or antibody fragment comprises
(a) the HCDR1 region of SEQ ID NO:8, the HCDR2 region of SEQ ID NO:9, the HCDR3 region of SEQ ID NO:10, the LCDR1 region of SEQ ID NO:11, the LCDR2 region of SEQ ID NO:12 and the LCDR3 region of SEQ ID NO:13,
(b) the HCDR1 region of SEQ ID NO:18, the HCDR2 region of SEQ ID NO:19, the HCDR3 region of SEQ ID NO:20, the LCDR1 region of SEQ ID NO:21, the LCDR2 region of SEQ ID NO:22 and the LCDR3 region of SEQ ID NO.: SEQ ID NO:23, or
(c) the HCDR1 region of SEQ ID NO:28, the HCDR2 region of SEQ ID NO:29, the HCDR3 region of SEQ ID NO:30, the LCDR1 region of SEQ ID NO:31, the LCDR2 region of SEQ ID NO:32 and the LCDR3 region of SEQ ID NO:33.

2. An isolated antibody or antibody fragment according to claim 1 , wherein said antibody or antibody fragment comprises
(a) the variable heavy region of SEQ ID NO:14 and the variable light region of SEQ ID NO:15,
(b) the variable heavy region of SEQ ID NO:24 and the variable light region of SEQ ID NO:25, or
(c) the variable heavy region of SEQ ID NO:34 and the variable light region of SEQ ID NO:35,
(i).

3. An isolated antibody according to claim 1 , wherein said antibody is of a lgG I subtype which has an effector function which is diminished compared to the wild type lgG I subtype.

4. The isolated antibody of claim 3 , wherein the aspartic acid residue at position 265 of said antibody (numbering according to the EU index) is exchanged for an alanine residue.

5. The isolated antibody or antibody fragment according to claim 1 , wherein said antibody or antibody fragment is a monoclonal antibody or a polyclonal antibody.

6. The isolated antibody or antibody fragment according to claim 1 , wherein said antibody is a human, humanized or chimeric antibody.

7. The isolated antibody or antibody fragment according to claim 1 , wherein said antibody is cross-reactive to cynomolgus M-CSF, mouse M-CSF and/or rat M-CSF.

8. The isolated antibody or antibody fragment according to claim 1 which inhibits M-CSF induced proliferation.

9. A composition comprising an isolated antibody or antibody fragment of claim 1 , and a pharmaceutically acceptable carrier.

10. A nucleic acid encoding an antibody or antibody fragment of claim 1 .

11. A vector comprising the nucleic acid of claim 10 .

12. An isolated host cell comprising a vector according to claim 11 .

Assignees

• Morphosys Ag

Inventors

• Dodeller Francis
• Rauchenberger Robert

Classifications

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K16/243 Primary

  Colony Stimulating Factors · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title